We Added 70 Companies and over 120 Funding Events

Top Deals This Week
This Week’s Lead Investors in Top Rounds
This Week in Clinical Phases
70 Life Science Companies Added

CipherBio Weekly Digest: Week of Feb 3 – Feb 9, 2022

This week we bring you news and events about $2.77B in deals, $391.90M in Series A, 70 companies and 29 investors added to our CipherBio platform.

$2.77B
Deals

$391.90M
Series A

$324.2M
Series B

$506.3M
Later Rounds

$1.2B
M&A/IPOs

70
New Companies on CipherBio

Sign Up For Your Free Account ➜

Top Deals This Week

Seismic Therapeutic raises $101M in Series A round led by Lightspeed Venture Partners. Endeavor BioMedicines raises $101M in Series B led by Ally Bridge Group and Avidity Partners. Also in Series B ConcertoCare raises $105M led by Wells Fargo Strategic Capital. Dewpoint Therapeutics gets $150M in Series C led by Softbank Vision Fund 2. Ventus Therapeutics raises $140M / Series B led by Softbank Vision Fund 2 and RA Capital Management. In Series F Lyra Health raises $235M led by Dragoneer Investment Group.

**See Investors Insights ➜**
Company	Round	Amount
Seismic Therapeutic	Series A	$101M
Endeavor BioMedicines	Series B	$101M
ConcertoCare	Series B	$105M
Dewpoint Therapeutics	Series C	$150M
Ventus Therapeutics	Series C	$140M
Lyra Health	Series F	$235M

This Week’s Lead Investors in Top Rounds

Lead investors this week are Lightspeed Venture Partners, Ally Bridge Group, Avidity Partners, Wells Fargo Strategic Capital, Softbank Vision Fund 2, RA Capital Management, Dragoneer Investment Group.

See Investors Insights ➜

This Week in Clinical Phases

In phase 1 Synthekine announces trial of STK-012 for the treatment of solid tumors. Also, Avacta Group announces a phase 1 trial of their product AVA6000. French-based ImCheck Therapeutics starts phase 2 trial of their anti-BTN3A monoclonal antibody ICT01. Acurx Pharmaceuticals starts their phase 2A trial of Ibezapolstat, their lead antibiotic candidate. Nanoscope Therapeutics starts a phase 2B trial of MCO-010 for gene therapy to restore vision. SaNOtize starts phase 3 trial of Nitric Oxide Nasal Spray (NONS) as an effective COVID-19 treatment. BioCardia receives FDA Breakthrough Device for the CardiAMP cell therapy system.

**See All Clinical Insights ➜**
Company	Product and Clinical Phase	Indications
Synthekine	STK-012, Phase 1	Oncology, Solid Tumors, Cancers and Other Neoplasms (NOS)
Avacta Group	AVA6000, Phase 1	Oncology, Cancers and Other Neoplasms (NOS)
ImCheck Therapeutics	ICT01, Phase 2	Melanoma, Cancers and Other Neoplasms (NOS), Gastric Cancer, Breast Cancer, Lymphoma, Prostate Cancer
Acurx Pharmaceuticals	Ibezapolstat, Phase 2A	Clostridium Difficile Infections (CDI), Bacterial Infections, Infections
Nanoscope Therapeutics	MCO-010, Phase 2B	Retinal Diseases, Orphan/Rare Diseases, Retinitis Pigmentosa, Eye Diseases, Gene Therapy
SaNOtize	Nitric Oxide Nasal Spray (NONS), Phase 3	COVID-19
BioCardia	CardiAMP, FDA Breakthrough Device	Heart Failure, Cardiovascular Health, Cell Therapy

Starfield, food & science technology, raised $100M in Series B round led by Primavera Capital Group, Lightspeed China Partners and Joy Capital. FlipDish raised $100M in Series C led by Tencent. In AgTech MycoWorks raised $125M in Series C to build a new alt-leather factory. WayCool raised $117M in Series D led by LightRock, LightBox, FMO and others.

70 Life Science Companies Added

This week we added 123 funding events, 70 life science companies and 29 investors.

15 of 70 Companies
**See Companies Insights ➜**
Resonant Link	Timber Pharmaceuticals	ConcertoCare
Waterdrop	Zero Acre Farms	Retailo
Vena Medical	Nemis Technologies	Lover
Rose Health	Penrod	DAMAE Medical
GreenLight Biosciences	Azooka Labs	Perfuze